MAPT and Alzheimer disease: In our previous pre-clinical work on AD, we have shown that the drug nilvadipine can reduce inflammation, decrease tau phosphorylation, and enhance A\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$ \beta $$\end{document}β clearance across the blood brain barrier (BBB), while improving cognitive functions [2, 23, 24].